These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 21757968)

  • 21. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
    Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
    Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Saxagliptin + metformin. Mostly disadvantages.
    Prescrire Int; 2013 Feb; 22(135):40. PubMed ID: 23444500
    [No Abstract]   [Full Text] [Related]  

  • 23. The Cause and Effect Relationship of Diabetes after Acute Pancreatitis.
    Śliwińska-Mossoń M; Bil-Lula I; Marek G
    Biomedicines; 2023 Feb; 11(3):. PubMed ID: 36979645
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pancreatogenic diabetes after pancreatic resection.
    Maeda H; Hanazaki K
    Pancreatology; 2011; 11(2):268-76. PubMed ID: 21734430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.
    Berkowitz SA; Krumme AA; Avorn J; Brennan T; Matlin OS; Spettell CM; Pezalla EJ; Brill G; Shrank WH; Choudhry NK
    JAMA Intern Med; 2014 Dec; 174(12):1955-62. PubMed ID: 25347323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study.
    Penfornis A; Blicklé JF; Fiquet B; Quéré S; Dejager S
    Vasc Health Risk Manag; 2014; 10():341-52. PubMed ID: 24966684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of TS-021 with metformin improves hyperglycemia and synergistically increases pancreatic β-cell mass in a mouse model of type 2 diabetes.
    Tajima A; Hirata T; Taniguchi K; Kondo Y; Kato S; Saito-Hori M; Ishimoto T; Yamamoto K
    Life Sci; 2011 Oct; 89(17-18):662-70. PubMed ID: 21872612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hemifacial Spasm as the Presenting Manifestation of Type 3c Diabetes Mellitus.
    Ghosh R; Roy D; Chatterjee S; Dubey S; Swaika BC; Mandal A; Benito-León J
    Tremor Other Hyperkinet Mov (N Y); 2021 Apr; 11():14. PubMed ID: 33981477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complications of Chronic Pancreatitis.
    Ramsey ML; Conwell DL; Hart PA
    Dig Dis Sci; 2017 Jul; 62(7):1745-1750. PubMed ID: 28281169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Management of type 2 diabetes: new or previous agents, how to choose?].
    Halimi S
    Presse Med; 2013 May; 42(5):861-70. PubMed ID: 23643613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug evaluation: vildagliptin-metformin single-tablet combination.
    Tahrani AA; Piya MK; Barnett AH
    Adv Ther; 2009 Feb; 26(2):138-54. PubMed ID: 19288260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.
    Barnett AH; Charbonnel B; Li J; Donovan M; Fleming D; Iqbal N
    Clin Drug Investig; 2013 Oct; 33(10):707-17. PubMed ID: 23949898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes.
    Ahrén B
    Expert Opin Emerg Drugs; 2008 Dec; 13(4):593-607. PubMed ID: 19046129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.
    Aston-Mourney K; Subramanian SL; Zraika S; Samarasekera T; Meier DT; Goldstein LC; Hull RL
    Am J Physiol Endocrinol Metab; 2013 Aug; 305(4):E475-84. PubMed ID: 23736544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Differential characteristics of type 2 diabetes in the elderly. Role of dipeptidyl peptidase 4 inhibitors].
    Formiga F; Gómez-Huelgas R; Rodríguez Mañas L
    Rev Esp Geriatr Gerontol; 2016; 51(1):44-51. PubMed ID: 26073221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.
    Currie CJ; Poole CD; Gale EA
    Diabetologia; 2009 Sep; 52(9):1766-77. PubMed ID: 19572116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus.
    Ji L; Han P; Wang X; Liu J; Zheng S; Jou YM; O'Neill EA; Golm GT; Engel SS; Kaufman KD; Shankar RR
    J Diabetes Investig; 2016 Sep; 7(5):727-36. PubMed ID: 27181998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
    Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
    BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
    Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
    Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin.
    Hayashi T; Murayama H; Shinfuku Y; Taniguchi T; Tsumiyama I; Oyama N
    Expert Opin Pharmacother; 2020 Jan; 21(1):121-130. PubMed ID: 31689132
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.